Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study)

被引：0

作者：

Pascual-Izquierdo, Cristina ^{[1
]}

Llacer-Ferrandis, Ma. Jose ^{[1
]}

de-la-Iglesia, Almudena ^{[2
]}

Monsalvo-Saornil, Silvia ^{[2
]}

Menor-Gomez, Maria ^{[3
]}

Gil-Fernandez, Juan Jose ^{[3
]}

Chica-Gullon, Esther ^{[4
]}

alvarez-Roman, Maria Teresa ^{[5
]}

Perez-Segura, Gloria ^{[6
]}

Zafra, Denis ^{[6
]}

Ortuzar-Pasalodos, Ariana ^{[7
]}

Gonzalez-Gascon-y-Marin, Isabel Teresa ^{[8
]}

Moreno, Gemma ^{[9
]}

Arquero-Portero, Teresa ^{[10
]}

Moreno-Carbonell, Marta ^{[1
]}

Revilla, Nuria ^{[10
]}

机构：

[1] Hosp Gen Univ Gregorio Maranon, Inst Invest Gregorio Maranon, Hematol, Madrid, Spain

[2] Hosp Univ Puerta Hierro, Hematol, Madrid, Spain

[3] Hosp Univ Principe Asturias, Hematol, Madrid, Spain

[4] Hosp Univ Getafe, Madrid, Spain

[5] Hosp Univ La Paz, Hematol, Madrid, Spain

[6] Hosp Univ 12 Octubre, Hematol, Madrid, Spain

[7] Hosp Univ Rey Juan Carlos, Hematol, Madrid, Spain

[8] Hosp Univ Infanta Leonor, Hematol, Madrid, Spain

[9] Hosp Univ Ramon & Cajal, Hematol, Madrid, Spain

[10] Hosp Univ Fdn Jimenez Diaz, Inst Invest Fdn Jimenez Diaz IIS FJD, Hematol, Madrid, Spain

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2025年 / 206卷 / 02期

关键词：

avatrombopag; immune thrombocytopenia; ITP; TPO-RA;

D O I：

10.1111/bjh.19975

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged >= 65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.

引用

页码：652 / 656

页数：5

共 50 条

[21] Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study
Machin, Nicoletta
Ragni, Margaret V.
Comer, Diane M.
Yabes, Jonathan G.
THROMBOSIS RESEARCH, 2018, 172 : 80 - 85
[22] Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study
Fangfang Sun
Jie Chen
Wanlong Wu
Shikai Geng
WenWen Xu
Shuhui Sun
Zhiwei Chen
Liyang Gu
Xiaodong Wang
Ting Li
Shuang Ye
Clinical Rheumatology, 2020, 39 : 3099 - 3104
[23] Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study
Sun, Fangfang
Chen, Jie
Wu, Wanlong
Geng, Shikai
Xu, WenWen
Sun, Shuhui
Chen, Zhiwei
Gu, Liyang
Wang, Xiaodong
Li, Ting
Ye, Shuang
CLINICAL RHEUMATOLOGY, 2020, 39 (10) : 3099 - 3104
[24] Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia
Hamzah, Roszymah
Yusof, Nurasyikin
Tumian, Nor Rafeah
Aziz, Suria Abdul
Basri, Nur Syahida Mohammad
Leong, Tze Shin
Ho, Kim Wah
Selvaratnam, Veena
Tan, Sen Mui
Jamil, Siti Afiqah Muhamad
JOURNAL OF BLOOD MEDICINE, 2022, 13 : 337 - 349
[25] Seasonal variations of incident primary immune thrombocytopenia in adults: An ecological study
Moulis, Guillaume
Guenin, Sophie
Limal, Nicolas
Michel, Marc
Bierling, Philippe
Godeau, Bertrand
Mahevas, Matthieu
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 37 : E26 - E28
[26] Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
Cai Xuan
Fu Haixia
Zhao Xiangyu
Lu Jin
Jiang Qian
Chang Yingjun
Huang Xiaojun
Zhang Xiaohui
中华医学杂志英文版, 2022, 135 (19)
[27] Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
Cai, Xuan
Fu, Haixia
Zhao, Xiangyu
Lu, Jin
Jiang, Qian
Chang, Yingjun
Huang, Xiaojun
Zhang, Xiaohui
CHINESE MEDICAL JOURNAL, 2022, 135 (19) : 2344 - 2350
[28] Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome
Grimaldi-Bensouda, Lamiae
Nordon, Clementine
Michel, Marc
Viallard, Jean-Francois
Adoue, Daniel
Magy-Bertrand, Nadine
Durand, Jean-Marc
Quittet, Philippe
Fain, Olivier
Bonnotte, Bernard
Morin, Anne-Sophie
Morel, Nathalie
Costedoat-Chalumeau, Nathalie
Pan-Petesch, Brigitte
Khellaf, Mehdi
Perlat, Antoinette
Sacre, Karim
Lefrere, Francois
Abenhaim, Lucien
Godeau, Bertrand
HAEMATOLOGICA, 2016, 101 (09) : 1039 - 1045
[29] Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study
Wang, Yong-Shuai
Wang, Wei
Zhang, Sai
Zhang, Shen-Yu
Shen, Ai-Zong
Song, Hua-Chuan
Yao, Huan-Zhang
Song, Rui-Peng
Meng, Fan-Zheng
Li, Lei
Nashan, Bjoern
Wang, Ji-Zhou
Liu, Lian-Xin
FRONTIERS IN PHARMACOLOGY, 2022, 13
[30] Spotlight on eltrombopag concentration in pediatric immune thrombocytopenia: A single-center observational study in China
Dong, Shuyue
Wang, Zhifa
Wang, Nan
Ma, Jingyao
Meng, Jinxi
Sun, Yixin
Cheng, Xiaoling
Wu, Runhui
PEDIATRIC INVESTIGATION, 2024, 8 (01) : 44 - 52

← 1 2 3 4 5 →